Insmed (NASDAQ:INSM) COO Sells $242,379.90 in Stock

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 2,370 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $242,379.90. Following the transaction, the chief operating officer directly owned 98,603 shares in the company, valued at approximately $10,084,128.81. The trade was a 2.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Roger Adsett also recently made the following trade(s):

• On Wednesday, April 1st, Roger Adsett sold 88,060 shares of Insmed stock. The stock was sold at an average price of $164.63, for a total value of $14,497,317.80.

Insmed Price Performance

INSM opened at $94.22 on Monday. The stock’s 50-day moving average price is $130.45 and its 200 day moving average price is $154.65. Insmed, Inc. has a 12-month low of $70.57 and a 12-month high of $212.75. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The firm has a market cap of $20.42 billion, a price-to-earnings ratio of -16.39 and a beta of 0.79.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. During the same quarter in the prior year, the company earned ($1.42) EPS. Insmed’s revenue was up 229.7% on a year-over-year basis. As a group, sell-side analysts expect that Insmed, Inc. will post -2.56 earnings per share for the current year.

Institutional Investors Weigh In On Insmed

Several large investors have recently bought and sold shares of the stock. Norges Bank purchased a new position in shares of Insmed in the 4th quarter valued at about $506,625,000. Vanguard Group Inc. increased its holdings in shares of Insmed by 13.0% in the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock valued at $2,870,957,000 after acquiring an additional 2,291,328 shares during the last quarter. RTW Investments LP increased its holdings in shares of Insmed by 57.0% in the 4th quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock valued at $842,855,000 after acquiring an additional 1,758,321 shares during the last quarter. Artisan Partners Limited Partnership increased its holdings in shares of Insmed by 49.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after acquiring an additional 1,623,342 shares during the last quarter. Finally, Orbis Allan Gray Ltd purchased a new position in shares of Insmed in the 2nd quarter valued at about $153,389,000.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Morgan Stanley raised Insmed from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $166.00 to $212.00 in a research note on Monday, March 30th. Roth Mkm restated a “buy” rating and set a $212.00 price target on shares of Insmed in a report on Friday, April 17th. Truist Financial cut their price target on Insmed from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a report on Tuesday, April 21st. Finally, Leerink Partners upped their price target on Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Insmed currently has an average rating of “Moderate Buy” and an average price target of $210.50.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.